Pertussis vaccine

Pertussis vaccine

Vaccine description
Target disease	Bordetella pertussis
Type	?
Clinical data
MedlinePlus	a682198
Pregnancy cat.	?
Legal status	?
Identifiers
ATC code	J07AJ01 J07AJ02
N (what is this?)  (verify)

Pertussis vaccine is a vaccine used against Bordetella pertussis.^[1]

It is a component of the DPT vaccine.

Older versions of the vaccine involved inactivated cells. Newer versions are acellular, and are less likely to provoke a febrile state.^[2]

In 2005, two new vaccine products were licensed for use in adolescents and adults that combine the tetanus and diphtheria toxoids with acellular pertussis (Tdap) vaccine. These vaccines are the first acellular pertussis-containing vaccines that make it possible to vaccinate adolescents and adults against pertussis.^[3]

All people need protection against these three diseases—diphtheria, tetanus, and pertussis. Routine booster doses are also needed throughout life. Older children and adults without documentation of ever receiving the basic series of shots should receive a primary series of three doses, properly spaced. A single dose of Tdap is recommended for people ages 11 through 64 years in place of one of the Td doses, preferably the next one needed.^[4]

Local reactions, such as fever, redness and swelling at the injection site, and soreness and tenderness where the shot was given, are not uncommon in children and adults. These minor local and systemic adverse reactions are much less common with acellular DTaP vaccine; however, a determination of more rare adverse effects can only be made when additional data are available following extended use of DTaP.

Estimates of acellular pertussis vaccine efficacy range from 84% to 85% in preventing typical whooping cough—a level believed to be far more efficacious than the previously-used whole cell pertussis vaccine.^[5]

References

This vaccine article is a stub. You can help Wikipedia by expanding it. v t e